年轻血浆输注在阿尔茨海默病症状改善血浆研究中的安全性、耐受性和可行性:一项随机临床试验
该研究在18例轻中度阿尔茨海默病痴呆患者中评估年轻新鲜冰冻血浆输注的安全性、耐受性和可行性,采用双盲交叉设计(9例)及开放标签扩展(9例)。未发生相关严重不良事件,最常见不良事件为高血压、头晕、窦性心动过缓、头痛和窦性心动过速,均为轻中度。作者认为年轻血浆治疗安全、耐受良好且可行,但样本量小、持续时间短且研究设计有变更,需进一步在更大规模双盲安慰剂对照试验中探索。
要点
- 在轻中度阿尔茨海默病患者中,年轻新鲜冰冻血浆输注未发生相关严重不良事件。
- 血浆组与安慰剂组其他不良事件无统计学显著差异,严重程度为轻中度。
- 平均访视依从性(n=18)为86%(四分位距87%-100%)。
核心结论
- 年轻新鲜冰冻血浆治疗安全、耐受良好且可行。
- 研究局限性为样本量小、持续时间短和研究设计变更。
- 结果需在更大规模双盲安慰剂对照临床试验中进一步探索。
研究设计与样本
- 血浆用于阿尔茨海默病症状改善(PLASMA)研究随机分配9例患者,采用双盲交叉方案,接受4次每周1次的年轻新鲜冰冻血浆(来自18至30岁男性供者)或生理盐水输注,随后6周洗脱并交叉至另一治疗4次。
- 开放标签修订后,9例患者仅接受4次每周1次的年轻新鲜冰冻血浆输注,其主观测量为非盲。
- 患者仅从斯坦福大学(三级学术医疗中心)招募,招募时间为2014年9月至2016年12月,达到目标时停止。
- 连续纳入18例 probable 轻中度阿尔茨海默病痴呆患者,简易精神状态检查评分12至24分(含),年龄50至90岁。
- 筛查31例患者,排除13例:11例不符合纳入标准,2例拒绝参与。
主要发现
- 交叉组(n=9)与开放标签组(n=9)在年龄(均值[标准差],74.17[7.96]岁)、性别(12例女性[67%])或基线简易精神状态检查评分(均值[标准差],19.39[3.24])方面无差异。
- 无相关严重不良事件;1例患者因荨麻疹停止参与,另1例因无关卒中停止参与。
- 血浆组(17例[94.4%])与安慰剂组(9例[100.0%])其他不良事件无统计学显著差异,严重程度为轻中度。
- 血浆组最常见不良事件包括高血压(3例[16.7%])、头晕(2例[11.1%])、窦性心动过缓(3例[16.7%])、头痛(3例[16.7%])和窦性心动过速(3例[16.7%])。
- 平均访视依从性(n=18)为86%(四分位距87%-100%),考虑因患者提前终止而减少的总访视要求后,依从性为96%(四分位距89%-100%)。
局限性
- 研究局限性为样本量小、持续时间短和研究设计变更。
- 结果需在更大规模双盲安慰剂对照临床试验中进一步探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Young mouse plasma restores memory in aged mice, but, to our knowledge, the effects are unknown in patients with Alzheimer disease (AD). OBJECTIVE: To assess the safety, tolerability, and feasibility of infusions of young fresh frozen plasma (yFFP) from donors age 18 to 30 years in patients with AD. DESIGN, SETTING, AND PARTICIPANTS: The Plasma for Alzheimer Symptom Amelioration (PLASMA) study randomized 9 patients under a double-blind crossover protocol to receive 4 once-weekly infusions of either 1 unit (approximately 250 mL) of yFFP from male donors or 250 mL of saline, followed by a 6-week washout and crossover to 4 once-weekly infusions of an alternate treatment. Patients and informants were masked to treatment and subjective measurements. After an open-label amendment, 9 patients received 4 weekly yFFP infusions only and their subjective measurements were unmasked. Patients were enrolled solely at Stanford University, a tertiary academic medical center, from September 2014 to December 2016, when enrollment reached its target. Eighteen consecutive patients with probable mild to moderate AD dementia, a Mini-Mental State Examination (score of 12 to 24 inclusive), and an age of 50 to 90 years were enrolled. Thirty-one patients were screened and 13 were excluded: 11 failed the inclusion criteria and 2 declined to participate. INTERVENTIONS: One unit of yFFP from male donors/placebo infused once weekly for 4 weeks. MAIN OUTCOME AND MEASURES: The primary outcomes were the safety, tolerability, and feasibility of 4 weekly yFFP infusions. Safety end point analyses included all patients who received the study drug/placebo. RESULTS: There was no difference in the age (mean [SD], 74.17 [7.96] years), sex (12 women [67%]), or baseline Mini-Mental State Examination score (mean [SD], 19.39 [3.24]) between the crossover (n = 9) and open-label groups (n = 9). There were no related serious adverse events. One patient discontinued participation because of urticaria and another because of an unrelated stroke. There was no statistically significant difference between the plasma (17 [94.4%]) and placebo (9 [100.0%]) cohorts for other adverse events, which were mild to moderate in severity. The most common adverse events in the plasma group included hypertension (3 [16.7%]), dizziness (2 [11.1%]), sinus bradycardia (3 [16.7%]), headache (3 [16.7%]), and sinus tachycardia (3 [16.7%]). The mean visit adherence (n = 18) was 86% (interquartile range, 87%-100%) and adherence, accounting for a reduction in the total visit requirement due to early patient discontinuation, was 96% (interquartile range, 89%-100%). CONCLUSIONS AND RELEVANCE: The yFFP treatment was safe, well tolerated, and feasible. The study's limitations were the small sample size, short duration, and change in study design. The results warrant further exploration in larger, double-blinded placebo-controlled clinical trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02256306.
引用
- Sha SJ, Deutsch GK, Tian L, et al. Safety, Tolerability, and Feasibility of Young Plasma Infusion in the Plasma for Alzheimer Symptom Amelioration Study: A Randomized Clinical Trial. JAMA Neurol. 2019. PMID: 30383097. doi:10.1001/jamaneurol.2018.3288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。